NCT06120504View on ClinicalTrials.gov

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

January 21, 2026

Study Completion Date

January 21, 2026

Conditions
Lymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Interventions
DRUG

PF-08046045

Given into the vein (IV; intravenously)

Trial Locations (17)

10021

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York

10065

Memorial Sloan Kettering Cancer Center-Main Campus, New York

10604

MSK Westchester., Harrison

11101

Memorial Sloan Kettering Cancer Center-Investigational Drug Service Pharmacy, Long Island City

11553

MSK Nassau., Uniondale

11725

MSK Commack., Commack

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

33136

University of Miami Hospital and Clinics, Miami

University of Miami, Miami

33146

University of Miami Hospital and Clinics - Lennar, Coral Gables

77030

The University of Texas MD Anderson Cancer Center, Houston

94304

Stanford Cancer Center / Blood and Marrow Transplant Program, Palo Alto

07920

MSK Basking Ridge, Basking Ridge

07601

Hackensack University Medical Center, Hackensack

07748

MSK Monmouth., Middletown

07645

MSK Bergen., Montvale

07652

Hackensack University Medical Center (From Road), Paramus

All Listed Sponsors
lead

Seagen, a wholly owned subsidiary of Pfizer

INDUSTRY